Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Promimic

16.25 SEK

+2.20 %

Less than 1K followers

PRO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+2.20 %
+6.21 %
+6.91 %
-10.71 %
-27.78 %
-40.91 %
+39.25 %
-
-0.20 %

Promimic specializes in biotechnology. The company develops biocompatible surfaces for implants and conducts research in surface modifications. Examples of specialist areas include surface modifications for osseointegration for orthopedic and dental implants. The largest operations are in Europe and America, where research and development is conducted in-house but also through partners. Promimic is headquartered in Mölndal, Sweden.

Read more
Market cap
307M SEK
Turnover
14.57K SEK
Revenue
43.98M
EBIT %
-18.92 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
24/2
2026

Annual report '25

19/5
2026

Interim report Q1'26

21/5
2026

General meeting '26

All
Press releases
ShowingAll content types
Regulatory press release11/19/2025, 6:30 AM

Promimic AB: Bästa kvartalet hittills i Q3 2025

Promimic
Regulatory press release10/14/2025, 2:00 PM

Valberedning utsedd i Promimic AB (publ)

Promimic
Press release9/22/2025, 12:38 PM

Analyst Group: Analyst Group intervjuar Promimics VD Magnus Larsson

Promimic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release8/22/2025, 5:30 AM

Promimic AB: Kvartal 2 Rekordmånga nya kundavtal

Promimic
Regulatory press release8/15/2025, 10:00 AM

Promimic AB byter Certified Adviser till Tapper Partners AB

Promimic
Regulatory press release5/22/2025, 2:00 PM

Kommuniké från årsstämma 2025 i Promimic AB (publ)

Promimic
Regulatory press release5/15/2025, 5:30 AM

Promimic AB: Strategiska affärer för tillväxt i Kvartal 1 2025

Promimic
Press release5/5/2025, 2:00 PM

Promimic AB: Fördjupat samarbete med Curiteva

Promimic
Press release4/23/2025, 7:00 AM

Promimic AB: Strategiskt samarbetsavtal med Lincotek

Promimic
Regulatory press release4/17/2025, 5:30 AM

Kallelse till årsstämma i Promimic AB (publ)

Promimic
Regulatory press release4/10/2025, 6:00 AM

Promimic AB: Promimic Årsredovisning 2024

Promimic
Regulatory press release3/3/2025, 10:15 AM

VD:n säljer del av sitt aktieinnehav i Promimic AB (publ)

Promimic
Regulatory press release2/25/2025, 6:30 AM

Promimic AB: Promimic Bokslutskommuniké 2024 och Kvartal 4: All-Time-High

Promimic
Press release2/17/2025, 3:00 PM

Promimic AB: Nya resultat visar att beläggning av implantat med HA[nano] Surface minskar förekomsten av bakterier

Promimic
Regulatory press release11/21/2024, 6:30 AM

Promimic AB: Tillväxt och tio nya godkännanden under tredje kvartalet

Promimic
Regulatory press release10/15/2024, 5:30 AM

Valberedning utsedd i Promimic AB (publ)

Promimic
Regulatory press release10/11/2024, 3:30 PM

Promimic AB: Promimic har löst in optionsprogrammet 2021-TO3

Promimic
Press release9/5/2024, 6:25 PM

Promimic AB: FSG ökar sitt ägande i Promimic

Promimic
Regulatory press release8/22/2024, 5:30 AM

Promimic AB: Nytt försäljningsrekord och nytt licensavtal under andra kvartalet

Promimic
Regulatory press release5/22/2024, 4:00 PM

Kommuniké från årsstämma 2024 i Promimic AB (publ)

Promimic
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.